Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Publications

Co-authored

  • Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. (2014). Thyroid dysfunction in patients with diffuse large B-cell lymphoma receiving lenalidomide is mediated by TNFalpha. Experimental Hematology. 2014 Oct 28. pii: S0301-472X(14)00715-2.
  • Johnson DB, Dahlman, KB, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. (2014). Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19(6):616-22.
  • Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson DB, Sosman J, Pao W, Zhao Z. (2014). A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Molecular Cancer Therapeutics. 13(7):1918-28.
  • Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. (2014). Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment. 145: 389-399.
  • Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. (2014). Beyond histology: Translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research. 20: 2264-2275.
  • Rexer BN, Chanthaphaychith S, Dahlman KB, Arteaga CL. (2014). Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Research. 16(1):R9.
  • Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired Resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discovery. 4: 80-93.
  • Wang Q, Jia P, Li F, Chen H, Ji H, Hucks, D, Dahlman KB, Pao W, Zhao Z. (2013) Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine. 5: 91.
  • Jia P, Jin H, Meador CB, Xia J, Ohashi K, Dahlman KB, Politi K, Zhao Z, Pao W (2013). Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-1445.
  • Dahlman KB*, Xia J*, Hutchinson K*, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle P, Hicks D, Bozon V, Glaspy JA, Netterville JL, Venencak-Jones C, Sosman J, Ribas A, Zhao Z, Pao W (2012). BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discovery. 2: 791-797 *These authors contributed equally. (subject of accompanying editorial Cancer Discovery (2012) 2:766-768)
  • Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo G, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS (2012). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to B-RAF inhibitors. Cancer Discovery. 2: 414-424.
  • Lovly C*, Dahlman KB*, Fohn L*, Su Z*, Dias-Santagata D, Hicks DJ, Hucks D, Berry, E, Terry C, Duke M Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate JA, Sosman J, Pao W (2012). Routine multiple mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE. 7: e35309. *These authors contributed equally.
  • Su Y, Kelley MC, Splittgerber RC, Kantrow S, Short S, Sobolik-Delmaire T, Dahlman KB, Jiang A, Shyr Y, Levy S, Sosman J, Richmond A (2012). RAF265 inhibits the growth of advanced human melanoma independent of BRAF mutation status. Clinical Cancer Research. 18: 2184-2198.
  • Shi H, Moriceau G, Kong X, Lee M, Ribas A, Koya R, Ng C, Chodon T, Nelson S, Lee H, Long G, Scolyer R, Kefford R, Sosman J, Dahlman KB, Lo R (2012) Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. 3: 724.
  • Poulikakos, PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Madhavi T, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit D (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480: 387-390.
  • Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A, Hayden JE, Dahlman KB, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18: 683-695.
 

Acknowledged

  • Lovly CM, McDonald T, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Lu W, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansen S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W (2014). Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature Medicine. 20: 1027-1034.
  • Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, CAntley LC, Winer E, Arteaga CL (2014). Stand Up to Cancer phase Ib study of pan-phosphoinositide-2-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 32(12):1202-9.
  • Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013). Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med. 5: 149-166
  • Lehmann BD*, Bauer JA*, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation. 121: 2750-2767. *These authors contributed equally.